دورية أكاديمية
Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids
| العنوان: | Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids |
|---|---|
| المؤلفون: | Bartalena L., Manetti L., Tanda M. L., Dell'Unto E., Mazzi B., Rocchi R., Barbesino G., Pinchera A., Marcocci C. |
| المساهمون: | Bartalena, L., Manetti, L., Tanda, M. L., Dell'Unto, E., Mazzi, B., Rocchi, R., Barbesino, G., Pinchera, A., Marcocci, C. |
| سنة النشر: | 2000 |
| المجموعة: | IRInSubria - Institutional Repository Insubria (Università degli Studi dell’Insubria) |
| مصطلحات موضوعية: | Adult, Aged, Antithyroid Agent, Biomarker, Case-Control Studie, Female, Glucocorticoid, Graves Disease, Human, Interleukin 1 Receptor Antagonist Protein, Linear Model, Male, Methimazole, Methylprednisolone, Middle Aged, Sialoglycoprotein, Smoking, Statistics, Nonparametric, Thyroxine, Treatment Outcome |
| الوصف: | OBJECTIVE: The aim of the present study was to evaluate serum soluble interleukin-1 receptor antagonist (sIL-1RA) concentration and its relationship with the degree of cigarette smoking in patients with Graves' ophthalmopathy (GO). DESIGN AND SUBJECTS: Twenty-two consecutive GO patients (20 women, two men; age range 25-68 years, mean 48 years; 12 smokers, 10 non- smokers) submitted to IV glucocorticoid pulses over a 3-month period. MEASUREMENTS: sIL-1RA levels were measured by an immunoenzymatic assay (sensitivity, 4 ng/l; normal range, 50-290 ng/l) before glucocorticoid treatment, after two months of therapy, and 3 months after drug withdrawal. RESULTS: Thirteen patients responded to treatment (59%; five smokers and eight non-smokers), nine were non-responders (41%; seven smokers and two nonsmokers). Baseline median sIL-1RA concentration did not differ in smokers and non-smokers (222 and 173 ng/l, respectively; P=0.69). Likewise, no significant differences were found between the two groups during treatment (537 and 389 ng/l, respectively; P=0.28); sIL-1RA concentration after treatment was higher in smokers (258 vs. 94 ng/l; P=0.02). There was no correlation between basal sIL-1RA levels and the degree of cigarette smoking. Likewise, there was no difference in sIL-1RA levels in responders and non- responders, either at baseline (186 vs. 216 ng/l; P= 0.83), during or after treatment. CONCLUSION: Our study suggests that circulating soluble interleukin-1 receptor antagonist levels, both at baseline and during glucocorticoid treatment, are neither influenced by cigarette smoking nor- predictive of subsequent response to glucocorticoid treatment. ; OBJECTIVE: The aim of the present study was to evaluate serum soluble interleukin-1 receptor antagonist (sIL-1RA) concentration and its relationship with the degree of cigarette smoking in patients with Graves' ophthalmopathy (GO). DESIGN AND SUBJECTS: Twenty-two consecutive GO patients (20 women, two men; age range 25-68 years, mean 48 years; 12 smokers, 10 non- smokers) ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/10792346; info:eu-repo/semantics/altIdentifier/wos/WOS:000087257900018; volume:52; issue:5; firstpage:647; lastpage:651; numberofpages:5; journal:CLINICAL ENDOCRINOLOGY; http://hdl.handle.net/11383/2102684Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-0034043547 |
| DOI: | 10.1046/j.1365-2265.2000.00988.x |
| الإتاحة: | https://doi.org/10.1046/j.1365-2265.2000.00988.xTest http://hdl.handle.net/11383/2102684Test |
| رقم الانضمام: | edsbas.A7C7AF45 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1046/j.1365-2265.2000.00988.x |
|---|